Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ENTA vs CAPR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CAPR Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–5 Matrix Metrics)

CAPR Overall Winner 6-Pillar Tally: ENTA 2 – 3 CAPR (1 Tie) Matrix Metrics: ENTA 5 – 5 CAPR

As of Nov 16, 2026, Capricor Therapeutics Inc (CAPR) is the stronger overall head-to-head candidate over Enanta Pharmaceuticals, Inc (ENTA) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). ENTA carries a Unified Composite Score of 46.2/100 (HOLD) at $10.79 (44.0x Forward P/E, -90.0% operating margin), whereas CAPR carries 28.0/100 (SELL) at $8.45 (78.7x Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While ENTA currently prints a higher short-term Unified Composite Score (46.2/100 HOLD vs. CAPR 28.0/100 SELL), CAPR captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -90.0% operating margin) and revenue trajectory (-7.9% vs. -21.6% YoY).
  • Technical & Structure Timing Caution: ENTA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0); meanwhile CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ENTA vs CAPR
ENTA NASDAQ
Enanta Pharmaceuticals, Inc
Pharmaceutical Preparations
$10.79
-1.82% 1D
Market Cap $326.2M
TTM Revenue $65M
Forward P/E 44.0x
Beta / 30D Vol 0.89β · 58% Vol
Unified Composite Score
46.2 / 100 HOLD
Tech 53.0 Fund 54.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.6%), weak momentum, RSI 43
RSI-14: 43.0 · SMA20: $11.18 · SMA50: $11.88
CAPR NASDAQ Head-to-Head Winner
Capricor Therapeutics Inc
Pharmaceutical Preparations
$8.45
-11.39% 1D
Market Cap $595.4M
TTM Revenue $11M
Forward P/E 78.7x
Beta / 30D Vol 1.50β · 151% Vol
Unified Composite Score
28.0 / 100 SELL
Tech 50.0 Fund 37.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.2% over 20 days), RSI 51
RSI-14: 51.4 · SMA20: $7.79 · SMA50: $8.08

6-Pillar Scorecard Institutional Category Breakdown (ENTA 2 – 3 CAPR)

Columns: Metric · ENTA · CAPR
1. Valuation Multiples ENTA
Forward P/E 44.0x 78.7x
Trailing P/E 44.0x 78.7x
PEG Ratio N/M 0.38x
EV / Revenue 5.3x 57.8x
2. Growth & Scale CAPR
Revenue Growth (YoY) -21.6% -7.9%
Earnings Growth (YoY) -66.2% +0.0%
TTM Revenue (USD) $65M $11M
Market Cap $326.2M $595.4M
3. Profitability & Quality CAPR
Gross Margin 100.0% N/A
Operating Margin -90.0% 0.0%
Net Profit Margin -96.9% 0.0%
Return on Equity (ROE) -70.1% -100.5%
4. Balance Sheet & Cash Flow ENTA
Cash Generation (TTM) -$37M -$146M
Cash Flow Margin -56.6% N/A
Net Cash / Leverage $22M Net Debt (0.55x D/E) $48M Net Debt (0.44x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CAPR
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 78.7% (11th %ile) 637.1% (89th %ile)
Put/Call OI Skew 0.31x (Call-Skewed) 1.57x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown ACCUMULATION · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ENTA (5) vs CAPR (5)
Institutional Metric ENTA CAPR Criterion Row Edge
Market Capitalization
Scale
$326.2M $595.4M Larger Scale CAPR
Trailing P/E Ratio
Valuation
44.0x 78.7x Lower Multiple ENTA
Forward P/E Ratio
Valuation
44.0x 78.7x Lower Multiple ENTA
Revenue Growth (YoY)
Growth
-21.6% -7.9% Higher Growth CAPR
Operating Margin (TTM)
Profitability
-90.0% 0.0% Higher Margin CAPR
Net Profit Margin
Profitability
-96.9% 0.0% Higher Margin CAPR
Return on Equity (ROE)
Capital Efficiency
-70.1% -100.5% Higher ROE ENTA
52-Week Range Position
Momentum
10% ($10–$17) 15% ($3–$40) Stronger Trend CAPR
Beta / 30D Volatility
Risk Regime
0.89β · 58% Vol 1.50β · 151% Vol Lower Realized Risk ENTA
Unified Institutional Score
Composite Signal
46.2 / 100 (HOLD) 28.0 / 100 (SELL) Higher Composite ENTA
Trailing 12M Revenue (USD)
Operating Scale
$65M $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 5.3x EV/Rev 0.38x PEG · 57.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$37M ($22M Net Debt (0.55x D/E)) -$146M ($48M Net Debt (0.44x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CAPR +28.65 pp
ENTA: -2.79% · CAPR: +25.86%
3M Horizon CAPR +38.15 pp
ENTA: -18.87% · CAPR: +19.28%
6M Horizon ENTA +51.13 pp
ENTA: -19.54% · CAPR: -70.67%
1Y Horizon CAPR +54.3 pp
ENTA: -7.94% · CAPR: +46.36%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ENTA Revenue CAPR Revenue ENTA Op. Margin CAPR Op. Margin Margin Leader
FY2018 $210M $0M 42.7% -917.0% ENTA
FY2019 $210M $0M 17.9% -769.5% ENTA
FY2020 $120M $0M -34.0% -4412.6% ENTA
FY2021 $100M $0M -112.9% -8549.9% ENTA
FY2022 $90M $0M -143.7% -1163.9% ENTA
FY2023 $80M $30M -173.2% -95.6% CAPR
FY2024 $70M $20M -179.9% -191.1% ENTA
FY2025 $70M N/A -130.7% N/A ENTA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ENTA BREAKDOWN
95d in phase · OBV NEUTRAL
Current IV 78.7%
IV Percentile 11th %ile
Put/Call OI Skew 0.31x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact ENTA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CAPR CONSOLIDATION
56d in phase · OBV ACCUMULATION
Current IV 637.1%
IV Percentile 89th %ile
Put/Call OI Skew 1.57x (Put-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CAPR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ENTA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $326.2M market capitalization and -90.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CAPR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $595.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ENTA vs CAPR Key Questions & Quantitative Answers

As of Nov 16, 2026, Capricor Therapeutics Inc (CAPR) is the stronger overall head-to-head candidate over Enanta Pharmaceuticals, Inc (ENTA) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). ENTA carries a Unified Composite Score of 46.2/100 (HOLD) at $10.79 (44.0x Forward P/E, -90.0% operating margin), whereas CAPR carries 28.0/100 (SELL) at $8.45 (78.7x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ENTA currently prints a higher short-term Unified Composite Score (46.2/100 HOLD vs. CAPR 28.0/100 SELL), CAPR captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -90.0% operating margin) and revenue trajectory (-7.9% vs. -21.6% YoY). Technical & Structure Timing Caution: ENTA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0); meanwhile CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CAPR leads the Growth & Scale pillar: ENTA posts -21.6% YoY revenue growth and -66.2% YoY earnings growth on $65M TTM revenue (100.0% gross margin, -90.0% operating margin), compared with CAPR at -7.9% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), ENTA cumulative revenue shifted -66.7% while CAPR shifted -33.3%. In operating R&D and SG&A reinvestment, ENTA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CAPR.

ENTA screens cheaper on headline valuation multiples. ENTA trades at 44.0x Forward P/E, 44.0x Trailing P/E, N/M PEG, and 5.3x EV/Revenue (-56.6% FCF margin), whereas CAPR trades at 78.7x Forward P/E, 78.7x Trailing P/E, 0.38x PEG, and 57.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ENTA (-70.1% ROE) versus CAPR (-100.5% ROE) capital efficiency.

In options market volatility and institutional positioning, ENTA carries 78.7% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.89β · 58% Vol realized risk). By comparison, CAPR carries 637.1% implied volatility (89th %ile, Extreme (>80th %ile)), a 1.57x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.50β · 151% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.